Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Genomic determinants of survival after biliary tract cancer resection.

Kashyap Koul, Franshisca Hayek, Ruizhe Chen et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16301

e16301 Background: Surgical resection is the mainstay for localized, resectable biliary tract cancers (BTCs). Although gen...

Oral fluoropyrimidines as alternatives to intravenous 5-fluorouracil in combination with immune checkpoint inhibitors for recurrent metastatic head neck squamous cell carcinoma.

Hsueh-Ju Lu, Yu-Wei Chiu, Chih-Yu Peng et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18015

e18015 Background: Based on the KEYNOTE-048 trial, immune checkpoint inhibitors (ICIs) with or without chemotherapy have b...

Pre-operative chemotherapy versus surgery first with peri-operative interventions in early triple-negative and HER2-positive breast cancer: An open-label, phase 3, randomized controlled trial (PRaCTiSE).

Shalaka Prakash Joshi, Rohini W. Hawaldar, Vaibhav Vanmali et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps659

TPS659 Background: Surgery is a mainstay of treatment of breast cancer. Neoadjuvant chemotherapy (NACT) has not proven to...

Effects of short-term fasting compared to free diet in ovarian cancer patients: Results from a two-arm pilot randomized trial.

Claudia Marchetti, Carolina Maria Sassu, Laura Vertechy et al. Jun 01, 2026 pp. 5517-5517 10.1200/jco.2026.44.16_suppl.5517

5517 Background: Short-term fasting (STF) may enhance chemotherapy efficacy by suppressing insulin-driven pro-survival sig...

Amivantamab in <i>EGFR</i> -mutated NSCLC with refractory brain or leptomeningeal metastases: A multi-center real-world study.

Chang Lu, Meng-Hang Yang, Zi-Jian Huang et al. Jun 01, 2026 pp. 8521-8521 10.1200/jco.2026.44.16_suppl.8521

8521 Background: The central nervous system (CNS), particularly after progression on third-generation EGFR TKIs, represent...

Guideline-concordant cancer screening among U.S. adults with and without cardiovascular risk factors.

Manav Dev Midha, Varun Aysola Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22565

e22565 Background: Uptake of age- and sex-appropriate cancer screening remains suboptimal in the United States. Patients w...

Maintenance pegylated liposomal doxorubicin (PLD) versus active surveillance for advanced soft tissue sarcoma patients who had controlled disease after standard anthracycline-based treatment (MELODY).

Tom Wei-Wu Chen, Yeh Chen Lee, Prabhat Ghanshyam Bhargava et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps11596

TPS11596 Background: The progression-free survival (PFS) associated with first-line chemotherapy for advanced soft tissue...

Texture and color enhancement imaging (TXI) for polyp detection in colorectal neoplasia screening: A meta-analysis of randomized controlled trials.

Haroon Alamy, Raj Nandan Chennuri, Noorul Hidhaya S et al. Jun 01, 2026 pp. 10582-10582 10.1200/jco.2026.44.16_suppl.10582

10582 Background: Colonoscopy remains the gold standard for preventing colorectal cancer; however, variable adenoma detect...

Exploring improved prognostication using PET/CT radiomics in relapsed/refractory, TP53-aberrant diffuse large B-cell lymphoma (DLBCL).

Vincenzo Pizzuti, Samvid Kotia, Muthiah Nachiappan et al. Jun 01, 2026 pp. 7070-7070 10.1200/jco.2026.44.16_suppl.7070

7070 Background: Patients (pts) with TP53-aberrant DLBCL have inferior progression-free survival (PFS) and overall surviva...

The expansion of hematopoietic cell transplantation in patients aged &gt;75 years: A CIBMTR analysis, 2019–2023.

Shubhank Goyal, Aura Calderon, Daniela Hernandez et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13769

e13769 Background: Hematopoietic cell transplantation (HCT) is increasingly utilized in older adults; however, patients ag...

Developing quality cancer survivorship care competencies for primary care: A modified Delphi study.

Youngjee Choi, Rebecca Lynne Eary, Melissa Erickson et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13780

e13780 Background: Most of the growing population of people living with and beyond cancer will access primary care. Howeve...

A real-world analysis of dyslipidemia and attributable risk in lorlatinib-treated ALK-positive lung cancer patients.

Siqing Jiang, Xingxiang Pu, Lin Wu et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24190

e24190 Background: Lorlatinib as a first-line treatment for ALK-positive NSCLC can significantly prolong survival, and the...

Correlative analysis of ctDNA in CheckMate-9X8 study of frontline treatment with mFOLFOX6, bevacizumab with or without nivolumab in metastatic colorectal cancer.

Jin Yao, Yong Huang, Rachel Tam et al. Jun 01, 2026 pp. 3584-3584 10.1200/jco.2026.44.16_suppl.3584

3584 Background: The CheckMate 9X8 study evaluated ctDNA as biomarker to predict treatment benefit in metastatic colorecta...

Surufatinib combined with anti-PD-1/PD-L1 antibody in the second line or monotherapy in third line treatment of advanced hepatocellular carcinoma: A single-arm, open-label, multi-center phase II study.

Lei Yang, Qing Gao, Jun Gong et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16172

e16172 Background: Surufatinib is a selective inhibitor of VEGFRs, FGFR1, and CSF-1R, demonstrating dual mechanisms of ant...

An indirect comparison of EGFR TKI combination therapies in advanced <i>EGFR</i> -mutated NSCLC: Comparing manual and AI-generated analyses.

Aysswarya Manoharan, Chinmay Jani, Sunwoo Han et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20625

e20625 Background: The treatment landscape for stage IV EGFR-mutated non-small cell lung cancer (NSCLC) is rapidly evolvin...

Envafolimab combined with lenvatinib and gemcitabine plus cisplatin in advanced biliary tract cancer as first-line treatment: A multicenter, single-arm, open-label, phase II study (ENLIGHTEN study).

Lixia Xu, Mengping Zhang, Chuankai Zhang et al. Jun 01, 2026 pp. 4152-4152 10.1200/jco.2026.44.16_suppl.4152

4152 Background: The prognosis of advanced biliary tract cancer (BTC) remains unsatisfactory despite the use of first-line...

Group-based versus individualized exercise programs in lung cancer: Results from the randomized crossover LungFit study.

Enric Carcereny, Oscar Martinez, Silvia Sanchez Martin et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20101

e20101 Background: Patients with lung cancer frequently experience reduced functional capacity and impaired quality of lif...

Phase 1 study of NTX1088, a first-in-class anti-PVR monoclonal antibody, as monotherapy and combined with pembrolizumab, in patients with advanced solid malignancies.

Sarina A. Piha-Paul, Marc Ryan Matrana, Gagandeep Brar et al. Jun 01, 2026 pp. 2518-2518 10.1200/jco.2026.44.16_suppl.2518

2518 Background: Poliovirus Receptor (PVR; CD155), a transmembrane protein upregulated across multiple solid tumors and as...

Pre-existing mental health diagnosis and colorectal cancer outcomes.

Hasiya Yusuf, Elham Babadi, Tarrant McPherson et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15711

e15711 Background: Mental health disorders are common among patients (pts) with cancer, sometimes associated with delays i...

Spatial PK/PD profiling in human ex vivo tumor slices to identify exposure-limited niches driving heterogeneous response to a TROP2-targeting ADC in NSCLC.

Corinne Ramos Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15040

e15040 Background: TROP2-targeting antibody–drug conjugates (ADCs) have demonstrated promising clinical activity in non-sm...

Prognostic role of ATM in gastric cancer: A systematic review and meta-analysis.

Aima Azhar, Muhammad Abdul Moiz, Amina Hassan et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16342

e16342 Background: Gastric adenocarcinoma remains one of the primary causes of cancer-related mortality worldwide. There i...

Randomized controlled trial of a psychosocial digital application (THRIVE-MM) for patients living with multiple myeloma.

Areej El-Jawahri, Cheri Marmarosh, Suzanne Hollman et al. Jun 01, 2026 pp. 1513-1513 10.1200/jco.2026.44.16_suppl.1513

1513 Background: Patients living with multiple myeloma (MM) struggle with considerable quality of life (QOL) impairments,...

A cardio-oncologic burden: Leukemia-associated arrhythmia mortality in the United States (1999-2023).

Fasil Chirankara, Elangovan Krishnan, Sophia Ahmed et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18634

e18634 Background: Leukemia remains a major contributor to cancer-related mortality in the United States. Cardiac arrhythm...

Trends in ovarian function suppression use among premenopausal women with breast cancer: A longitudinal analysis from 2015-2023.

Jacqueline Jialin Tao, Ling Chen, David DeStephano et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12694

e12694 Background: Ovarian function suppression (OFS) combined with endocrine therapy (ET) using tamoxifen or an aromatase...

Prospective clinical activity and preclinical basis of panitumumab-based EGFR blockade in SMARCB1-deficient renal medullary carcinoma (RMC): A collaborative multi-institutional study.

Pavlos Msaouel, Eric S. Rupe, Xinyue Chen et al. Jun 01, 2026 pp. 4520-4520 10.1200/jco.2026.44.16_suppl.4520

4520 Background: RMC is a rare, exceptionally aggressive malignancy that predominantly affects young individuals of Africa...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page